rovalpituzumab tesirine
abbvie
['rova,(-approval),(-microvascular)']
 the $autl #asco23 data seem decent, and obe-cel looks approvable, but: 
Once had a blue tick. Journalist at Evaluate Vantage. Interested in: oncology, immunology. Not interested in: what stock you bought today.